| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3161 | 2019 |
| An integrated metabolic atlas of clear cell renal cell carcinoma AA Hakimi, ED Reznik, CH Lee, CJ Creighton, AR Brannon, A Luna, ... Cancer cell 29 (1), 104-116, 2016 | 664 | 2016 |
| Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors MH Taylor, CH Lee, V Makker, D Rasco, CE Dutcus, J Wu, DE Stepan, ... Journal of Clinical Oncology 38 (11), 1154, 2020 | 370 | 2020 |
| mTOR pathway as a target in tissue hypertrophy CH Lee, K Inoki, KL Guan Annu. Rev. Pharmacol. Toxicol. 47, 443-467, 2007 | 240 | 2007 |
| Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53 CH Lee, K Inoki, M Karbowniczek, E Petroulakis, N Sonenberg, ... The EMBO journal 26 (23), 4812-4823, 2007 | 197 | 2007 |
| Update on tumor neoantigens and their utility: why it is good to be different CH Lee, R Yelensky, K Jooss, TA Chan Trends in immunology 39 (7), 536-548, 2018 | 165 | 2018 |
| Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma MI Carlo, S Mukherjee, D Mandelker, J Vijai, Y Kemel, L Zhang, ... JAMA oncology 4 (9), 1228-1235, 2018 | 157 | 2018 |
| Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, ... The lancet oncology 22 (7), 946-958, 2021 | 136 | 2021 |
| A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma MI Carlo, AM Molina, Y Lakhman, S Patil, K Woo, J DeLuca, CH Lee, ... The oncologist 21 (7), 787-788d, 2016 | 102 | 2016 |
| Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker, A Knezevic, ... Journal of Clinical Oncology 40 (21), 2333, 2022 | 100 | 2022 |
| Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin J Xu, CG Pham, SK Albanese, Y Dong, T Oyama, CH Lee, ... The Journal of clinical investigation 126 (9), 3526-3540, 2016 | 98 | 2016 |
| A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma T Funakoshi, CH Lee, JJ Hsieh Cancer treatment reviews 40 (4), 533-547, 2014 | 95 | 2014 |
| Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non–clear cell renal cell carcinoma MH Voss, AM Molina, YB Chen, KM Woo, JL Chaim, DT Coskey, ... Journal of Clinical Oncology 34 (32), 3846, 2016 | 79 | 2016 |
| Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma P Msaouel, AL Hong, EA Mullen, MB Atkins, CL Walker, CH Lee, ... Clinical genitourinary cancer 17 (1), 1-6, 2019 | 67 | 2019 |
| CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor L Wu, C Runkle, HJ Jin, J Yu, J Li, X Yang, T Kuzel, C Lee Oncogene 33 (4), 504-513, 2014 | 65 | 2014 |
| Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial SA Funt, M Lattanzi, K Whiting, H Al-Ahmadie, C Quinlan, MY Teo, ... Journal of Clinical Oncology 40 (12), 1312, 2022 | 64 | 2022 |
| Comprehensive molecular characterization and response to therapy in fumarate hydratase–deficient renal cell carcinoma JP Gleeson, I Nikolovski, R Dinatale, M Zucker, A Knezevic, S Patil, Y Ged, ... Clinical Cancer Research 27 (10), 2910-2919, 2021 | 57 | 2021 |
| Metastatic chromophobe renal cell carcinoma: Presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes Y Ged, YB Chen, A Knezevic, J Casuscelli, A Redzematovic, RG DiNatale, ... Clinical genitourinary cancer 17 (3), e678-e688, 2019 | 55 | 2019 |
| Lenvatinib+ pembrolizumab in patients with renal cell carcinoma: updated results CH Lee, V Makker, DW Rasco, MH Taylor, DE Stepan, RC Shumaker, ... J Clin Oncol 36 (15_suppl), 4560, 2018 | 50 | 2018 |
| Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma MH Voss, D Chen, M Marker, AA Hakimi, CH Lee, JJ Hsieh, JJ Knox, ... British Journal of Cancer 114 (6), 642-649, 2016 | 49 | 2016 |
